Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster ...

This was the stock's third consecutive day of gains.

Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% ...

In the closing of the recent trading day, Vertex Pharmaceuticals (VRTX) stood at $408.18, denoting a +0.72% change from the preceding trading day.

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity” third ...

Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today. The company’s ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) had its target price hoisted by Scotiabank from $426.00 to $430.00 in a ...

We recently compiled a list of the Jim Cramer Talked About These 17 Stocks After The Fed’s Rate Cut. In this article, we are ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against the ...

Equities researchers at Zacks Research upped their Q3 2025 earnings per share estimates for shares of Vertex Pharmaceuticals ...

Vertex Pharmaceuticals Inc (VRTX) stock saw a modest uptick, ending the day at $408.18 which represents a slight increase of $2.91 or 0.72% from the prior close of $405.27. The stock opened at $401.53 ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price ...